louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06525285: MCAF and EMD With and Without CTG Wall Technique for the Treatment of Class III and IV Gingival recessions-a Randomized Control Trial
Official title: Modified Coronally Advanced Flap and Enamel Matrix Derivative With and Without Connective Tissue Graft Wall Technique for the Treatment of Class III and IV Gingival recessions-a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Gingival Recession
Lead sponsor: Krishnadevaraya College of Dental Sciences & Hospital
Sponsor class: OTHER
First posted: 2024-07-29
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Research is to compare and evaluate the clinical outcomes of the Connective tissue graft wall technique with modified coronally advanced flap to improve root coverage and clinical attachment levels in Miller's class III and IV gingival recession.

Detailed description: Research is to compare and evaluate the clinical outcomes of the Connective tissue graft wall technique with modified coronally advanced flap to improve root coverage and clinical attachment levels in Miller's class III and IV gingival recession. The objectives is to assess the probing pocket depth reduction, clinical attachment level gain, patient esthetic evaluation, complete root coverage and mean root coverage. the control group will be treated with modified coronally advanced flap with connective tissue graft and enamel matrix derivative and the study group will be treated with modified coronally advanced flap with connective tissue graft wall and enamel matrix derivative. The total number of participants included will be 24 (Control-12; Study-12) with a 6 month follow up.

Eligibility criteria: Inclusion Criteria:

* Participants aged 18-60 years
* Systemically healthy individuals
* Participants with Miller's Class III and IV or Cairo's RT3 gingival recession in maxillary and mandibular anteriors.
* Participants with Nordland and Tarnow's papillary recession of either I, II or III.
* Presence of interdental PPD, CAL and recession
* Radiographic evidence of interdental bone loss
* No prior experience of root coverage procedures
* Able to achieve good oral hygiene and control gingivitis in the whole of the dentition (FMPS \< 25% and FMBS \< 25%).

Exclusion Criteria:

* Grade III mobile teeth
* Pathologically migrated teeth
* Endodontically treated teeth
* Open contacts
* Pregnancy and lactating women
* Participants with systemic conditions
* Untreated periodontitis
* Persistence of uncorrected gingival trauma from tooth brushing
* Self-reported current smoking
* Presence of medical contraindications to elective surgery

Primary outcomes:
measure: Root coverage
timeFrame: 6 months
Secondary outcomes:
measure: Gingival health and evaluation
timeFrame: 6 months
Other outcomes:
Locations:
city: Bengaluru
country: India
facility: Dr. Prabhuji MLV
state: Karnataka
Study officials:
References:
Clinical trial NCT00944385: Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement
Official title: Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Abnormal Aortic Valve
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2009-07-23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.


Eligibility criteria: Inclusion Criteria:

* 40% below of output of left ventricle
* tricuspid valve failure from moderate to severe
* urgent surgery required
* infectious endocarditis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
affiliation: Severance Hospital
name: Younglan Kwak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06783985: Clinical Application of Carbon Nanoparticles in Lymph Node Tracing and Surgery Guiding of Colorectal Cancer
Official title: Clinical Application of Carbon Nanoparticles in Lymph Node Tracing and Surgery Guiding of Colorectal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Keywords: carbon nanoparticle
colorectal cancer
lymph node
Lead sponsor: Sir Run Run Shaw Hospital
Sponsor class: OTHER
First posted: 2025-01-20
Enrollment: 146
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study was conducted in Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. Patient information and samples were obtained from patients undergoing radical resection of colorectal cancer in the colorectal surgery department of the hospital.

Brief summary: This trial aims to clarify the relationship between carbon nanoparticles labeled lymph nodes and lymph node metastasis in different lymph node regions of colorectal cancer, and to clarify the application value of carbon nanoparticles in lymph node dissection in colorectal cancer surgery.


Eligibility criteria: Inclusion Criteria:

1. a diagnosis of colorectal cancer;
2. endoscopic injection of CNP suspension preoperatively
3. planned radical resection of colorectal cancer
4. older than 18 years of age

Exclusion Criteria:

(a) emergency surgery;

Primary outcomes:
measure: The relationship between carbon nanoparticle stained lymph nodes and metastatic lymph nodes
timeFrame: From enrollment to the pathology report at 2 weeks
Secondary outcomes:
measure: Carbon nanoparticle stained lymph nodes from different lymph node groups.
timeFrame: From enrollment to the pathology report at 2 weeks
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Sir Run Run Shaw hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT04294485: Physical Therapy Intervention in Pleural Effusion
Official title: Physical Therapy Intervention in Hospitalized Pleural Effusion Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pleural Effusion
Keywords: Physical therapy
Pleural effusion
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2020-03-04
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To know the effects of a physical therapy intervention in patients hospitalized with pleural effusion. The investigators will study the effects of the intervention in hospital stay, health status, psychologica distress and quality of life.


Eligibility criteria: Inclusion Criteria:

* Inclusion criteria were pleural effusion patients hospitalized.

Exclusion Criteria:

* Inability to provide informed consent.
* Presence of psychiatric or cognitive disorders.
* Progressive neurological disorders, organ failure, or inability to cooperate.
* Patients who had experienced another pleural effusion in the previous month.

Primary outcomes:
measure: EuroQol-5 Dimensions visual analogue scale score
timeFrame: Baseline
measure: EuroQol-5 Dimensions visual analogue scale score
timeFrame: Up to 7 days
measure: EuroQol-5 Dimensions visual analogue scale score
timeFrame: Up to 3 months
measure: EuroQol-5 Dimensions index score
timeFrame: Baseline
measure: EuroQol-5 Dimensions index score
timeFrame: Up to 7 days
measure: EuroQol-5 Dimensions index score
timeFrame: Up to 3 months
Secondary outcomes:
measure: Functional capacity
timeFrame: Baseline
measure: Functional capacity
timeFrame: Up to 7 days
measure: Functional capacity
timeFrame: Up to 3 months
Other outcomes:
Locations:
city: Granada
country: Spain
facility: Department of Physical Therapy
Study officials:
References:
Clinical trial NCT06833385: Comparative Evaluation of Pediatric Patient Comfort, Time, and Preference Between Digital Scans and Rubber Base Impressions. Crossover Study Randomized Controlled Trial
Official title: Comparative Evaluation of Pediatric Patient Comfort, Time, and Preference Between Digital Scans and Rubber Base Impressions. Crossover Study Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Pediatric Patient With Early Loss of Primary Teeth
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-02-18
Enrollment: 30
Sex: ALL
Minimum age (years): 6
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The comfort of impression methods and the time they require are important because it is known that children are more stressed in their encounter with the dentist than the elderly, and their chairside times are shorter. The comparison of impression methods in terms of comfort, preference, and time has been studied only in young adults or adult patients. thus this study will assess pediatric patient comfort, time, and preference between digital scans and rubber base impressions.


Eligibility criteria: Inclusion Criteria:

* cooperative healthy 6-11 years old child

Exclusion Criteria:

* uncooperative with experience with technique

Primary outcomes:
measure: Patient Preference for Impression Technique
timeFrame: Immediately after the second impression (within the same visit)
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Dentistry
Study officials:
References:
Clinical trial NCT02782585: Manual Therapy Techniques on Cervical Spine and Psychological Interaction
Official title: Hypoalgesic Effects of Three Different Manual Therapy Techniques on Cervical Spine and Psychological Interaction: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Keywords: neck pain
Manual therapy
psychological interaction
Lead sponsor: Fondazione Don Carlo Gnocchi Onlus
Sponsor class: OTHER
First posted: 2016-05-25
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Manual therapy (MT) techniques applied over cervical region have over both local (neck) and distant regions (elbow) in both asymptomatic and symptomatic populations. Neurophysiological mechanisms are hypothesized to explain the underlying effects, with effects originating from peripheral mechanisms, spinal cord and supraspinal mechanisms.

There is also an increasing interest in the study of the role of psychological variables in the treatment success in neck pain. Psychological variables, like anxiety catastrophizing or kinesiophobia are related to poor prognosis in the development of pain outcomes and disability in neck pain, being the Fear-Avoidance Model of pain one of the most tested models in this field.


Eligibility criteria: Inclusion Criteria:

* Neck pain

Exclusion Criteria:

* myelopathy
* fracture
* infection
* dystonia
* tumor
* inflammatory disease
* fibromyalgia
* or osteoporosis

Primary outcomes:
measure: Change from Pressure Pain Thresholds (PPT) at 24 hours
timeFrame: 24 hours, 5 minutes after the treatment
measure: Change from State-Trait Anxiety Inventory subscale (STAI-E) at 24 hours
timeFrame: 24 hours, 5 minutes after the treatment
Secondary outcomes:
measure: Beck depression Inventory (BDI-II)
timeFrame: 24 hours, 5 minutes after the treatment
measure: Tampa Scale for Kinesiophobia
timeFrame: 24 hours, 5 minutes after the treatment
Other outcomes:
Locations:
Study officials:
affiliation: Don Gnocchi Foundation
name: JORGE H VILLAFAÑE, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Alonso-Perez JL, Lopez-Lopez A, La Touche R, Lerma-Lara S, Suarez E, Rojas J, Bishop MD, Villafane JH, Fernandez-Carnero J. Hypoalgesic effects of three different manual therapy techniques on cervical spine and psychological interaction: A randomized clinical trial. J Bodyw Mov Ther. 2017 Oct;21(4):798-803. doi: 10.1016/j.jbmt.2016.12.005. Epub 2016 Dec 22.
Clinical trial NCT05418985: The Effect of Monthly Text Message Reminder After Training on Beliefs and Practice Behaviors Regarding Women's Breast Self Examination: Randomized Controlled Study
Official title: The Effect of Monthly Text Message Reminder After Training on Beliefs and Practice Behaviors Regarding Women's Breast Self Examination: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Women's Breast Self Examination Beliefs
Women's Breast Self Examination Practice
Lead sponsor: Kahramanmaras Sutcu Imam University
Sponsor class: OTHER
First posted: 2022-06-15
Enrollment: 83
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A randomized control trial was made to examine the effects of of monthly text message reminder after training on beliefs and practice behaviors regarding women's breast self examination.


Eligibility criteria: Inclusion Criteria:

* Between the ages of 20-69,
* Able to speak and understand Turkish,
* At least primary school graduate,
* Not in pregnancy or postpartum period,
* Not in the breastfeeding process,
* Menarche,
* No current diagnosis of breast cancer,
* No breast disease that may affect the examination finding.

Exclusion Criteria:

* Those who did not complete the training on BSE,
* Those who want to leave the research,
* Those who had pregnancy during the research and
* Those who do not fill in the data forms sent to their e-mail addresses despite being reminded by message three times.

Primary outcomes:
measure: Women's beliefs about breast self-exam levet (mean ± SD)
timeFrame: 3 months after BSE education
Secondary outcomes:
measure: Behaviors of women performing breast self-examination
timeFrame: 3 months after BSE education
Other outcomes:
Locations:
city: Kahramanmaras
country: Turkey
facility: Kahramanmaras Sutcu Imam University
Study officials:
affiliation: Kahramanmaras Sutcu Imam University
name: Hilal ALKAN, Student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03162185: Serotonin and Motor Plasticity
Official title: The Effects of Serotonergic Challenge on Motor Learning and Neuroplasticity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Healthy Controls
Keywords: Neuroplasticity
SSRI
Motor Learning
Lead sponsor: Max Planck Institute for Human Cognitive and Brain Sciences
Sponsor class: OTHER
Collaborators: name: University of Leipzig
First posted: 2017-05-22
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: With this study, the investigators aim to test whether acute administration of selective serotonin reuptake inhibitors (SSRI) improves motor performance in a sequential motor learning task in comparison to placebo in healthy humans.

Detailed description: Microdialysis findings in animal models provide evidence for a monoaminergic augmentation of motor function. However, this evidence is largely limited to noradrenaline and dopamine, with little evidence to support a similar effect for serotonin. What remains to be tested therefore, is whether acute serotonergic administration induces neural or behavioral changes during motor learning also. Using a sample of 60 female participants (with the possible inclusion of male participants at a later date), the investigators aim to test the effects of a serotonergic challenge on motor learning and plasticity in healthy participants.

Eligibility criteria: Inclusion Criteria:

* female
* right-handed
* healthy
* has taken oral contraceptives (ovulation inhibitor) continuously for at least 3 months
* has read and agreed to study parameters

Exclusion Criteria:

* tattoos on head or neck
* non-removable metal on or in body
* alcohol abuse
* is currently taking medication
* smokes more than 3 cigarettes per day
* positive drug test
* pregnancy
* plays an instrument professionally
* plays videogames more than 2 hours per week
* is a professional athlete
* suffers from migraines
* has taken part in another study, where motor learning skills and/or medication is a factor, in the last 3 months
* heart rhythm disorders (long QT)
* hypertension
* calcium or magnesium deficiency
* neurological disorders
* chronic metabolic disorders
* liver or kidney diseases
* immunodeficiency
* endocrine disorders
* psychiatric disorders
* tumors
* injuries to the head and brain

Primary outcomes:
measure: Pinch Force Task.
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Leipzig
country: Germany
facility: Max Planck Institute for Cognition and Brain Sciences
state: Saxony
Study officials:
affiliation: Max Planck Institute for Human Cognitive and Brain Sciences
name: Arno Villringer
role: STUDY_CHAIR
affiliation: Max Planck Institute for Human Cognitive and Brain Sciences
name: Julia Sacher
role: STUDY_DIRECTOR
References:
Clinical trial NCT00147485: A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Official title: A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of AG-024322, An Inhibitor Of Cyclin-Dependent Kinase 1, 2 And 4, Administered Intravenously Daily For 5 Days Every 3 Weeks To Patients With Advanced Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasms
Lymphoma, Non-Hodgkin
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-07
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.

Detailed description: The study was prematurely discontinued due to the inability of the compound to adequately differentiate from other treatment options in the clinical endpoint and necessary product profile on April 13, 2007. Safety profile was not the reason that led to the discontinuation of the program.

Eligibility criteria: Inclusion Criteria:

* Advanced solid tumors or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition
* Adequate blood cell counts, kidney function and liver function and and ECOG score of 0 or 1.

Exclusion Criteria:

* Prior high-dose chemotherapy requiring hemapoietic stem cell rescue
* Previous radiation therapy to \>25% of the bone marrow
* Active or unstable cardiac disease or history of heart attack within 6 months

Primary outcomes:
measure: To test the safety of AG-024322 when taken by people who have cancer
measure: To find the AG-024322 dose that should be used in future clinical trials that will study effectiveness
measure: To assess how the human body handles blood concentrations of AG-024322
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Pfizer Investigational Site
state: Massachusetts
city: Boston
country: United States
facility: Pfizer Investigational Site
state: Massachusetts
city: Boston
country: United States
facility: Pfizer Investigational Site
state: Massachusetts
city: Philadelphia
country: United States
facility: Pfizer Investigational Site
state: Pennsylvania
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602.
Clinical trial NCT05247385: Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
Official title: Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2022-02-18
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with Ticagrelor placebo in stable patients with coronary artery disease

Detailed description: This was a prospective, double blinded, randomized trial that compared platelet inhibition and adenosine levels with ticagrelor (180mg loading dose, followed by 90 mg BID) versus prasugrel (60mg loading dose, followed by 10 mg QD) .

Patients were eligible if they were between 18 and 75 years old, were on aspirin without P2Y12 inhibitor at baseline and \> 1 year after documented ACS. Platelet aggregation was compared with the Multiplate ADP® assay, performed at baseline and after 15 days on study medication. Adenosine plasma levels were measured with high performance liquid chromatography at the same time points

Eligibility criteria: Inclusion Criteria:

* between 18 and 75 years old
* were on aspirin
* without P2Y12 inhibitor at baseline
* \> 1 year after documented acute coronary syndrome

Exclusion Criteria:

* use of oral anticoagulation or P2Y12 at baseline
* Weight \< 60kg
* History of tia or stroke
* Any coagulation disorders
* Refuse to sign the written consent

Primary outcomes:
measure: To compare platelet inhibition between the two groups (ticagrelor and prasugrel)
timeFrame: 15 days
measure: To compare adenosine levels between the two groups (ticagrelor and prasugrel)
timeFrame: 15 days
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Heart Institute (InCor) / University of São Paulo
state: Sao Paulo
Study officials:
References: